“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Saturday, August 30, 2025

Baxalta Incorporated


Baxalta Incorporated products

A

  • ADVATE (Antihemophilic Factor Recombinant) – Treatment for Hemophilia A with recombinant factor VIII

E

  • ERYTHROPOIETIN (biosimilar) – Therapy for anemia (various formulations under its immuno-oncology and biopharma offerings)

F

  • FEIBA (Anti-Inhibitor Coagulant Complex) – Used in Hemophilia A or B patients who have developed inhibitors against standard factor replacement therapies

G

  • GAMMAGARD LIQUID (intravenous immunoglobulin) – Immunodeficiency therapy for patients needing IgG supplementation

H

  • HYQVIA (Immune Globulin Infusion 10% with Recombinant Hyaluronidase) – Subcutaneous immunoglobulin delivery for primary immunodeficiency patients

O

  • ONCASPAR (pegaspargase) – Pegylated enzyme for treatment of acute lymphoblastic leukemia (ALL), particularly in pediatric cases

R

  • RUCONEST (recombinant human C1 esterase inhibitor) – Management of acute hereditary angioedema (HAE) attacks



on

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)